The macrophage at the intersection of immunity and metabolism in obesity

Diabetology & Metabolic Syndrome

M Constantine Samaan¹ 

[1] Division of Pediatric Endocrinology, Department of Pediatrics, McMaster Children's Hospital, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada

关键词: liver;    adipose tissue;    muscle;    chemokines;    cytokines;    macrophage;    inflammation;    type 2 diabetes;    Obesity;   

Others  :  817535
DOI  :  10.1186/1758-5996-3-29

 received in 2011-07-23, accepted in 2011-10-28,  发布年份 2011

【 摘 要 】

Obesity is a worldwide pandemic representing one of the major challenges that societies face around the globe. Identifying the mechanisms involved in its development and propagation will help the development of preventative and therapeutic strategies that may help control its rising rates.

Obesity is associated with chronic low-grade inflammation, and this is believed to be one of the major contributors to the development of insulin resistance, which is an early event in obesity and leads to type 2 diabetes when the pancreas fails to keep up with increased demand for insulin. In this review, we discuss the role of macrophages in mediation of inflammation in obesity in metabolic organs including adipose tissue, skeletal muscle and liver. The presence of immune cells at the interface with metabolic organs modulates both metabolic function and inflammatory responses in these organs, and may provide a potential therapeutic target to modulate metabolic function in obesity.

【 授权许可】

   
2011 Samaan; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]WHO Fact sheet: Obesity and overweight [http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/] webcite (Accessed July-12th-2011)
• [2]Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. The Lancet 2011, 378(9785):31-40.
• [3]Kelly T, Yang W, Chen CS, Reynolds K, He J: Global burden of obesity in 2005 and projections to 2030. Int J Obes 2008, 32(9):1431-1437.
• [4]Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95(5):2409-2415.
• [5]Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259(5091):87-91.
• [6]Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008, 118(9):2992-3002.
• [7]Asferg C, Jensen JS, Marott JL, Appleyard M, Mogelvang R, Jensen GB, Jeppesen J: Markers of inflammation and hemodynamic measurements in obesity: Copenhagen City Heart Study. Am J Hypertens 2009, 22(4):451-456.
• [8]Bullo M, Casas-Agustench P, Amigo-Correig P, Aranceta J, Salas-Salvado J: Inflammation, obesity and comorbidities: the role of diet. Public Health Nutr 2007, 10(10A):1164-1172.
• [9]Clement K, Vignes S: [Inflammation, adipokines and obesity]. Rev Med Interne 2009, 30(9):824-832.
• [10]Ferrante AW Jr: Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007, 262(4):408-414.
• [11]Greenberg AS, Obin MS: Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006, 83(2):461S-465S.
• [12]Hotamisligil GS: Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes (Lond) 2008, (32 Suppl 7):S52-54.
• [13]Hurt RT, Frazier TH, Matheson PJ, Cave MC, Garrison RN, McClain CJ, McClave SA: Obesity and inflammation: III. Curr Gastroenterol Rep 2007, 9(4):307-308.
• [14]Hurt RT, Frazier TH, Matheson PJ, Cave MC, Garrison RN, McClain CJ, McClave SA: Obesity and inflammation: II. Curr Gastroenterol Rep 2007, 9(4):306-307.
• [15]Hardy OT, Perugini RA, Nicoloro SM, Gallagher-Dorval K, Puri V, Straubhaar J, Czech MP: Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity. Surgery for Obesity and Related Diseases 2011, 7(1):60-67.
• [16]Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112(12):1821-1830.
• [17]Neels JG, Olefsky JM: Inflamed fat: what starts the fire? J Clin Invest 2006, 116(1):33-35.
• [18]Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112(12):1796-1808.
• [19]Andel M, Polak J, Kraml P, Dlouhy P, Stich V: [Chronic mild inflammation links obesity, metabolic syndrome, atherosclerosis and diabetes]. Vnitr Lek 2009, 55(7-8):659-665.
• [20]Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, Glass CK, Neels JG, Olefsky JM: A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007, 282(48):35279-35292.
• [21]Senn JJ: Toll-like Receptor-2 Is Essential for the Development of Palmitate-induced Insulin Resistance in Myotubes. Journal of Biological Chemistry 2006, 281(37):26865-26875.
• [22]Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid induced insulin resistance. The Journal of Clinical Investigation 2006, 116(11):3015-3025.
• [23]Takeda K, Kaisho T, Akira S: Toll-like receptors. Annual Review of Immunology 2003, 21(1):335-376.
• [24]Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, Philpott DJ, Klip A: NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance. Endocrinology 2010, 151(12):5624-5637.
• [25]Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C, Rodriguez A, Gil MJ, Cienfuegos JA, Fruhbeck G: Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 2007, 17(11):1464-1474.
• [26]Dinarello CA: Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 1997, 11(3):91-103.
• [27]Kabelitz D, Medzhitov R: Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2007, 19(1):1-3.
• [28]Matsuzawa Y, Shimomura I, Kihara S, Funahashi T: Importance of adipocytokines in obesity-related diseases. Horm Res 2003, 60(Suppl 3):56-59.
• [29]Nishimura S, Manabe I, Nagai R: Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med 2009, 8(41):55-60.
• [30]Sell H, Dietze-Schroeder D, Kaiser U, Eckel J: Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006, 147(5):2458-2467.
• [31]Bergman RN, Ader M: Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus. Trends in Endocrinology and Metabolism 2000, 11(9):351-356.
• [32]van Herpen NA, Schrauwen-Hinderling VB: Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav 2008, 94(2):231-241.
• [33]Turpin SM, Ryall JG, Southgate R, Darby I, Hevener AL, Febbraio MA, Kemp BE, Lynch GS, Watt MJ: Examination of 'lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice. J Physiol 2009, 587(Pt 7):1593-1605.
• [34]Sell H, Eckel J: Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc 2009, 68(4):378-384.
• [35]Kleinridders A, Schenten D, Konner AC, Belgardt BF, Mauer J, Okamura T, Wunderlich FT, Medzhitov R, Bruning JC: MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 2009, 10(4):249-259.
• [36]Velloso LA, Araujo EP, de Souza CT: Diet-induced inflammation of the hypothalamus in obesity. Neuroimmunomodulation 2008, 15(3):189-193.
• [37]Wisse BE, Schwartz MW: Does hypothalamic inflammation cause obesity? Cell Metab 2009, 10(4):241-242.
• [38]Yu J, Shi L, Wang H, Bilan PJ, Yao Z, Samaan MC, He Q, Klip A, Niu W: Conditioned medium from hypoxia-treated adipocytes renders muscle cells insulin resistant. Eur J Cell Biol 2011, 90(12):1000-1015.
• [39]Trayhurn P, Wang B, Wood IS: HIF-1alpha protein rather than mRNA as a marker of hypoxia in adipose tissue in obesity: focus on "inflammation is associated with a decrease of lipogenic factors in omental fat in women," by Poulain-Godefroy et al. Am J Physiol Regul Integr Comp Physiol 2008, 295(4):R1097. author reply R1098
• [40]Ye J: Emerging Role of Adipose Tissue Hypoxia in Obesity and Insulin Resistance. Int J Obes (Lond) 2009, 33(1):54-66.
• [41]Calabro P, Yeh ET: Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem 2007, 42:63-91.
• [42]Clement K, Vega N, Laville M, Pelloux V, Guy-Grand B, Basdevant A, Vidal H: Adipose tissue gene expression in patients with a loss of function mutation in the leptin receptor. Int J Obes Relat Metab Disord 2002, 26(12):1533-1538.
• [43]Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999, 341(12):879-884.
• [44]Farooqi IS, O'Rahilly S: Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009, 89(3):980S-984S.
• [45]Harsch IA, Bergmann T, Koebnick C, Wiedmann R, Ruderich F, Hahn EG, Konturek PC: Adiponectin, resistin and subclinical inflammation--the metabolic burden in Launois Bensaude Syndrome, a rare form of obesity. J Physiol Pharmacol 2007, (58 Suppl 1):65-76.
• [46]La Cava A, Alviggi C, Matarese G: Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 2004, 82(1):4-11.
• [47]Martin SS, Qasim A, Reilly MP: Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008, 52(15):1201-1210.
• [48]McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S: Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88(12):6098-6106.
• [49]Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92(3):347-355.
• [50]Trayhurn P, Wood IS: Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005, 33(Pt 5):1078-1081.
• [51]Elgazar-Carmon V, Rudich A, Hadad N, Levy R: Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res 2008, 49(9):1894-1903.
• [52]Takeya M: [Monocytes and macrophages--multifaced cell population involved in inflammation, atherosclerosis, and obesity]. Nippon Rinsho 2005, 63(Suppl 4):117-122.
• [53]Goodpaster BH, Wolf D: Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes. Pediatr Diabetes 2004, 5(4):219-226.
• [54]Shoelson SE, Lee J, Yuan M: Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S49-52.
• [55]Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100(12):7265-7270.
• [56]Marette A: Molecular mechanisms of inflammation in obesity-linked insulin resistance. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S46-48.
• [57]Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S53-55.
• [58]Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, Wu HY, Weiner HL: Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 107(21):9765-9770.
• [59]Lumeng CN, Maillard I, Saltiel AR: T-ing up inflammation in fat. Nat Med 2009, 15(8):846-847.
• [60]Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, et al.: T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28(7):1304-1310.
• [61]Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK: Tumor Necrosis Factor-α Induces Skeletal Muscle Insulin Resistance in Healthy Human Subjects via Inhibition of Akt Substrate 160 Phosphorylation. Diabetes 2005, 54(10):2939-2945.
• [62]Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li Jw, Young DB, Barbosa M, Mann M, Manning A, et al.: IKK-1 and IKK-2: Cytokine-Activated IkB Kinases Essential for NF-kB Activation. Science 1997, 278(5339):860-866.
• [63]Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396(6706):77-80.
• [64]Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11(2):191-198.
• [65]Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS: A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 2008, 3(9):e3151..
• [66]Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
• [67]Aguirre V, Uchida T, Yenush L, Davis R, White MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000, 275(12):9047-9054.
• [68]Solinas G, Karin M: JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction. The FASEB Journal 24(8):2596-2611.
• [69]Hotamisligil GS: Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005, 54(Suppl 2):S73-78.
• [70]Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O'Brien WR, et al.: PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 2004, 114(6):823-827.
• [71]Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, Sampson SR, Ohba M, Kuroki T, LeRoith D, Zick Y: Insulin stimulates PKCzeta -mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 2001, 276(17):14459-14465.
• [72]Haasch D, Berg C, Clampit JE, Pederson T, Frost L, Kroeger P, Rondinone CM: PKCtheta is a key player in the development of insulin resistance. Biochem Biophys Res Commun 2006, 343(2):361-368.
• [73]Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI: Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007, 117(3):739-745.
• [74]Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, Ferrante AW Jr: Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 2010, 120(10):3466-3479.
• [75]Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9(5):367-377.
• [76]Patsouris D, Neels JG, Fan W, Li PP, Nguyen MT, Olefsky JM: Glucocorticoids and thiazolidinediones interfere with adipocyte-mediated macrophage chemotaxis and recruitment. J Biol Chem 2009, 284(45):31223-31235.
• [77]Goodpaster BH, He J, Watkins S, Kelley DE: Skeletal Muscle Lipid Content and Insulin Resistance: Evidence for a Paradox in Endurance-Trained Athletes. Journal of Clinical Endocrinology & Metabolism 2001, 86(12):5755-5761.
• [78]van Loon LJC, Koopman R, Manders R, van der Weegen W, van Kranenburg GP, Keizer HA: Intramyocellular lipid content in type 2 diabetes patients compared with overweight sedentary men and highly trained endurance athletes. American Journal of Physiology - Endocrinology And Metabolism 2004, 287(3):E558-E565.
• [79]Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, et al.: Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle. Journal of Biological Chemistry 2002, 277(52):50230-50236.
• [80]Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106(2):171-176.
• [81]Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
• [82]Bourlier V, Bouloumie A: Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab 2009, 35(4):251-260.
• [83]Bruun JM, Lihn AS, Pedersen SB, Richelsen B: Monocyte Chemoattractant Protein-1 Release Is Higher in Visceral than Subcutaneous Human Adipose Tissue (AT): Implication of Macrophages Resident in the AT. J Clin Endocrinol Metab 2005, 90(4):2282-2289.
• [84]Chavey C, Lazennec G, Lagarrigue S, Clape C, Iankova I, Teyssier J, Annicotte JS, Schmidt J, Mataki C, Yamamoto H, et al.: CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 2009, 9(4):339-349.
• [85]Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K: Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 2007, 148(2):868-877.
• [86]Janeway CA, Medzhitov R: Innate Immune Recognition. Annual Review of Immunology 2002, 20(1):197-216.
• [87]Karagiannides I, Pothoulakis C: Obesity, innate immunity and gut inflammation. Curr Opin Gastroenterol 2007, 23(6):661-666.
• [88]Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature 2007, 449(7164):819-826.
• [89]Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR: Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008, 57(12):3239-3246.
• [90]Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR: Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56(1):16-23.
• [91]Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117(1):175-184.
• [92]Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity 32(5):593-604.
• [93]Martinez FO, Helming L, Gordon S: Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
• [94]Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM: Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes 2007, 31(9):1420-1428.
• [95]Zeyda M, Stulnig TM: Adipose tissue macrophages. Immunology Letters 2007, 112(2):61-67.
• [96]Hume DA: The mononuclear phagocyte system. Curr Opin Immunol 2006, 18(1):49-53.
• [97]Hume DA: Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunol 2008, 1(6):432-441.
• [98]Gordon S: The macrophage: past, present and future. Eur J Immunol 2007, 37(Suppl 1):S9-17.
• [99]Gordon S: Macrophage heterogeneity and tissue lipids. J Clin Invest 2007, 117(1):89-93.
• [100]Varin A, Gordon S: Alternative activation of macrophages: immune function and cellular biology. Immunobiology 2009, 214(7):630-641.
• [101]Ricardo-Gonzalez RR, Red Eagle A, Odegaard JI, Jouihan H, Morel CR, Heredia JE, Mukundan L, Wu D, Locksley RM, Chawla A: IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2010, 107(52):22617-22622.
• [102]Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, et al.: Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447(7148):1116-1120.
• [103]Odegaard JI, Chawla A: Alternative macrophage activation and metabolism. Annu Rev Pathol 2011, 6:275-297.
• [104]Cybulsky MI, Lichtman AH, Hajra L, Iiyama K: Leukocyte adhesion molecules in atherogenesis. Clin Chim Acta 1999, 286(1-2):207-218.
• [105]Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7(9):678-689.
• [106]Aron-Wisnewsky J, Tordjman J, Poitou C, Darakhshan F, Hugol D, Basdevant A, Aissat A, Guerre-Millo M, Clement K: Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab 2009, 94(11):4619-4623.
• [107]Geissmann Fdr, Gordon S, Hume DA, Mowat AM, Randolph GJ: Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 10(6):453-460.
• [108]Charriére G, Cousin B, Arnaud E, André M, Bacou F, Pénicaud L, Casteilla L: Preadipocyte Conversion to Macrophage. Journal of Biological Chemistry 2003, 278(11):9850-9855.
• [109]Cousin B, Andre M, Casteilla L, Penicaud L: Altered macrophage-like functions of preadipocytes in inflammation and genetic obesity. J Cell Physiol 2001, 186(3):380-386.
• [110]Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P, Casteilla L, Penicaud L: A role for preadipocytes as macrophage-like cells. FASEB J 1999, 13(2):305-312.
• [111]Aqel NM, Ball RY, Waldmann H, Mitchinson MJ: Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 1984, 53(3):265-271.
• [112]Palmer AM, Murphy N, Graham A: Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis 2004, 173(1):27-38.
• [113]Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y: Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009, 202(1):152-161.
• [114]Wellen KE, Hotamisligil GS: Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112(12):1785-1788.
• [115]Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005, 115(5):1111-1119.
• [116]de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, Burkey BF: Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance. Diabetes 2001, 50(8):1863-1871.
• [117]Suganami T, Ogawa Y: Adipose tissue macrophages: their role in adipose tissue remodeling. Journal of Leukocyte Biology 2010, 88(1):33-39.
• [118]Hotamisligil GS: Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999, 107(2):119-125.
• [119]Hotamisligil GS: Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000, 24(Suppl 4):S23-27.
• [120]Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414(6865):799-806.
• [121]Dietze D, Koenen M, Röhrig K, Horikoshi H, Hauner H, Eckel J: Impairment of Insulin Signaling in Human Skeletal Muscle Cells by Co-Culture With Human Adipocytes. Diabetes 2002, 51(8):2369-2376.
• [122]Holloway GP, Bonen A, Spriet LL: Regulation of skeletal muscle mitochondrial fatty acid metabolism in lean and obese individuals. Am J Clin Nutr 2009, 89(1):455S-462.
• [123]Samokhvalov V, Bilan PJ, Schertzer JD, Antonescu CN, Klip A: Palmitate- and lipopolysaccharide-activated macrophages evoke contrasting insulin responses in muscle cells. Am J Physiol Endocrinol Metab 2009, 296(1):E37-46.
• [124]Hong E-G, Ko HJ, Cho Y-R, Kim H-J, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, et al.: Interleukin-10 Prevents Diet-Induced Insulin Resistance by Attenuating Macrophage and Cytokine Response in Skeletal Muscle. Diabetes 2009, 58(11):2525-2535.
• [125]Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, et al.: Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007, 117(6):1658-1669.
• [126]Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG: Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 2008, 8(4):301-309.
• [127]Varma V, Yao-Borengasser A, Rasouli N, Nolen GT, Phanavanh B, Starks T, Gurley C, Simpson P, McGehee RE Jr, Kern PA, et al.: Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab 2009, 296(6):E1300-1310.
• [128]Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA: Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005, 54(8):2305-2313.
• [129]Bruun JM, Helge JW, Richelsen B, Stallknecht B: Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006, 290(5):E961-967.
• [130]Tordjman J, Guerre-Millo M, Clement K: Adipose tissue inflammation and liver pathology in human obesity. Diabetes Metab 2008, 34(6 Pt 2):658-663.
• [131]Clementi AH, Gaudy AM, van Rooijen N, Pierce RH, Mooney RA: Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2009, 1792(11):1062-1072.
• [132]Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN, Ables EV, Ferrante AW Jr: C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010, 59(4):916-925.
• [133]Yang S, IglayReger H, Kadouh H, Bodary P: Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia 2009, 52(5):972-981.
• [134]Park EJ, Lee JH, Yu G-Y, He G, Ali SR, Holzer RG, ÷sterreicher CH, Takahashi H, Karin M: Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell 2010, 140(2):197-208.